Get the latest news, insights, and market updates on CMPS (COMPASS Pathways plc). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Verano Holdings Ended Legal Battle with Vireo Growth; The Company Also Reported Third Quarter 2025 Financial Results Jushi Holdings’ Subsidiary is Targeting DoorDash and Total Wine in Landmark Lawsuit Over Illegal Hemp THC Sales Key Takeaways; Psychedelic Sector Compass Pathways Expanded Leadership and Research to Advance Precision Mental Health Treatments Clearmind […] Nov 2, 2025 - $CMPS
Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors
LONDON & NEW YORK, October 29, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a particular focus on neuroscience. Oct 29, 2025 - $CMPS
Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
LONDON & NEW YORK, October 28, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an update on recent developments, on November 4, 2025. Oct 28, 2025 - $CMPS
Design Therapeutics Appoints Justin Gover to Board of Directors
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company Sep 10, 2025 - $CMPS
COMPASS Pathways Plc (CMPS)’ Psilocybin Therapy Hits Phase 3 Success in Depression
We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. COMPASS Pathways Plc is one of them. COMPASS Pathways Plc (NASDAQ:CMPS), a biotechnology company specializing in innovative mental health treatments, is developing COMP360, a psilocybin-based therapy in late-stage development for treatment-resistant depression (TRD). COMP360 has received FDA Breakthrough Therapy designation […] Sep 2, 2025 - $CMPS
Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
LONDON & NEW YORK, September 02, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of results from an open-label Phase 2 study evaluating the safety and tolerability of a single-dose of 25 mg of investigational COMP360 synthetic psilocybin treatment in 22 patients with post-traumatic stress disorder (PTSD). The Phase 2 study findings, previously disclosed in Ma Sep 2, 2025 - $CMPS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple